June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Preparation for a Gene Therapy Trial for LCA5-Associated Retinal Degenerations: Treatment Potential in Patients and Dose-ranging Studies in Non-human Primates
Author Affiliations & Notes
  • Paris Margaritis
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Jean Bennett
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Steven Chomistek
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Vidyullatha Vasireddy
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Ivan Shpylchak
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Zhangyong Wei
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Angela Luo
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Junwei Sun
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Shangzhen Zhou
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Jennifer Pham
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Albert M Maguire
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Katherine E. Uyhazi
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Tomas S Aleman
    Ophthalmology, Center for Advanced Retinal and Ocular Therapeutics (CAROT), University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Paris Margaritis Accugen, Code C (Consultant/Contractor), Opus Genetics, Code F (Financial Support), Gyroscope, Code F (Financial Support); Jean Bennett Accugen, Code C (Consultant/Contractor), Sparing Vision, Code C (Consultant/Contractor), Splice Bio, Code C (Consultant/Contractor), Spark Therapeutics, Code C (Consultant/Contractor), Frontera, Code C (Consultant/Contractor), Gyroscope, Code F (Financial Support), Opus Genetics, Code O (Owner), REGENX BIO, Code S (non-remunerative); Steven Chomistek None; Vidyullatha Vasireddy SwanBio Therapeutics, Code E (Employment); Ivan Shpylchak None; Zhangyong Wei None; Angela Luo None; Junwei Sun Accugen, Code F (Financial Support), Opus Genetics, Code O (Owner); Shangzhen Zhou Accugen, Code F (Financial Support); Jennifer Pham None; Albert Maguire Spark Therapeutics, Code F (Financial Support), REGENX BIO, Code F (Financial Support); Katherine Uyhazi NIH KO8, Code F (Financial Support); Tomas Aleman Opus Genetics, Code F (Financial Support), REGENX BIO, Code F (Financial Support), EDITAS, Code F (Financial Support), Spark Therapeutics, Code F (Financial Support)
  • Footnotes
    Support  Opus Genetics SRA
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4141 – F0378. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paris Margaritis, Jean Bennett, Steven Chomistek, Vidyullatha Vasireddy, Ivan Shpylchak, Zhangyong Wei, Angela Luo, Junwei Sun, Shangzhen Zhou, Jennifer Pham, Albert M Maguire, Katherine E. Uyhazi, Tomas S Aleman; Preparation for a Gene Therapy Trial for LCA5-Associated Retinal Degenerations: Treatment Potential in Patients and Dose-ranging Studies in Non-human Primates. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4141 – F0378.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mutations in LCA5, which encodes lebercilin, account for one of the most severe forms of early-onset blindness, Leber congenital amaurosis (LCA5-LCA). Currently, there are no treatments for this disease. In our previous studies, early delivery of a AAV8-hLCA5 by subretinal injection in knockout mice partially reversed the severe retinal degeneration. In this study we explore the treatment potential of a group of patients with LCA5-LCA and assessed the safety of subretinal delivery of AAV8-hLCA5 in non-human primates (NHPs) in a dose-ranging study.

Methods : Six patients (ages 6-31 years) with LCA5-LCA underwent ophthalmic exams, full-field stimulus testing, and multimodal imaging with fundus autofluorescence and spectral-domain optical coherence tomography over 3- 5 years. In anticipation of Good Laboratory Practices (GLP) studies, we assessed the safety of subretinal injections of two doses (3E10vg and 1E11vg) of AAV8-hLCA5in NHPs. A control animal was injected with excipient. Retinal imaging matching the protocols used in patients was performed prior to euthanasia (d43 post-injection); retina tissue was evaluated for histopathology and LCA5 immunofluorescence.

Results : Visual acuity in the patients ranged from light perception to 20/200 and there was at least ~4 log units of dark-adapted sensitivity loss. Vision declined slightly during the observation period in some patients. Despite the severe retinal dysfunction, patients showed detectable photoreceptors in the pericentral and midperipheral retina. Subretinal delivery of AAV8-hLCA5 at 3E10 or 1E11vg/eye in NHPs was well-tolerated. There were mild injection-related changes in retinal architecture. There were minimal inflammatory cells in the vitreous and mild thinning of the outer nuclear layer in the eye injected with the higher dose (1E11 vg). AAV8-hLCA5 transduces photoreceptors and RPE cells in the exposed area in the NHP retina.

Conclusions : Detectable but severely dysfunctional photoreceptors in the central and midperipheral retina of patients with LCA5-LCA suggest these regions may be targets for gene augmentation. Subretinal delivery of AAV8-hLCA5 was safe at 1E10vg and there was mild inflammation at 1E11vg. The results of this study provide guidance for the doses to be used in a GLP NHP study and ultimately a human clinical trial.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×